Newcomer Mark sold $1.8M of PAYS

Newcomer Mark (CEO) sold 150,000 shares of Paysign, Inc. (PAYS) at $11.88 ($1.78M total) on 2026-08-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Newcomer Mark
Published Aug 8, 2026, 12:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 8, 2026, 12:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PAYS
Neutral
medium confidence
Mentioned
$PAYS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PAYSNeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price, and post-transaction holdings, with confirmation that it was executed under a pre-arranged Rule 10b5-1 plan.

02

Market read

A disclosed insider sale of roughly $1.78M at $11.8757 is unlikely to be a standalone fundamental catalyst, but it can influence short-term sentiment and positioning.

03

What to watch

Traders may over-weight insider selling; the key missing context is whether there were concurrent buys, changes in guidance, or other catalysts not mentioned in this filing.

Relevance 5/10Novelty 5/10Timing: SEC Form 4 filed 2026-08-07, transaction dated 2026-08-06

Background

This is an SEC Form 4 insider transaction disclosure for Paysign, Inc. (PAYS).

Company-level read

Ticker impact

$PAYSNeutralMedium confidence
Context

Paysign CEO and 10% owner Mark Newcomer sold 150,000 shares on 2026-08-06 for about $1.78M under a 10b5-1 plan.

Expected impact

Likely limited, short-lived sentiment impact; follow-through depends on broader tape and any additional insider activity.

Evidence & confidence

Form 4 provides a concrete transaction size and price, but the presence of a pre-arranged 10b5-1 plan reduces the signal strength versus discretionary selling.

Market effects

No sector-level implications are provided beyond a single-company insider sale.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect routine liquidity rather than bearish fundamentals, so price reaction may be overstated.

Key entities

  • Paysign, Inc.

    Company whose CEO/10% owner executed an open-market sale disclosed on Form 4.

  • Mark Newcomer

    CEO, officer/director/10% owner who sold 150,000 shares at $11.8757 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PAYSMedAI 8/10

Paysign (PAYS) Q3 2026 Earnings Call Transcript

Paysign (PAYS) reported Q3 2026 earnings, highlighting growth in its patient affordability business with revenue doubling to $16.6M YoY. Plasma revenue rose 7.5% to $13.8M. The company expects to offset a loss of 113 plasma centers with new clients. Patient affordability drove strong margins and operating leverage, while Apherion, a plasma industry software, is under regulatory review.

$PAYSHigh

Paysign Reports Record Third Quarter 2026 Revenue of $30.8 Million, Up 43%; Operating Margin More Than Triples to 23.8%

Paysign, Inc. (PAYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Earnings Release Paysign Reports Record Third Quarter 2026 Revenue of $30.8 Million, Up 43%; Operating Margin More Than Triples to 23.8% Patient Affordability Growth Drives Revenue and Margin Expansion Raises Full Year 2026 Gross Margin, Net Income, GAAP EPS and Adju

$PAYSHigh

Paysign Reports Record Second Quarter 2026 Revenue of $28.3 Million, Up 48%; Raises Full-Year Outlook

Paysign, Inc. (PAYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Earnings Release Paysign Reports Record Second Quarter 2026 Revenue of $28.3 Million, Up 48%; Raises Full-Year Outlook Growth Driven by Continued Momentum in Plasma and Patient Affordability Businesses Mix Shift and Expense Discipline Continue to Drive Gross and Oper